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 The Jak-stat pathway is critical for cellular proliferation and is commonly found 
to be deregulated in many solid tumors as well as hematological malignancies. Such 
findings have spurred the development of novel therapeutic agents that specifically 
inhibit Jak2 kinase, thereby suppressing tumor cell growth. Tyrphostin AG490, the first 
described Jak2 inhibitor, displays poor pharmacology and requires high concentrations 
for anti-tumor activities. Our research group screened a small library of AG490 
structural analogues and identified WP1130 as a potent inhibitor of Jak2 signaling. 
However, unlike AG490, WP1130 did not directly inhibit Jak2 kinase activity. Our results 
show that WP1130 induces rapid ubiquitination and subsequent re-localization of Jak2 
into signaling incompetent aggresomes. In addition to Jak2, WP1130 also induces 
accumulation of other ubiquitinated proteins without inhibiting 20S proteasome activity. 
Further analysis of the mechanism of action of WP1130 revealed that WP1130 acts as 
a partly selective DUB inhibitor. It specifically inhibits the deubiquitinase activity of 
USP9x, USP5, USP14 and UCH37. WP1130 mediated inhibition of tumor-associated 
DUBs resulted in down-regulation of anti-apoptotic and up-regulation of pro-apoptotic 
proteins, such as MCL-1 and p53 respectively. Our results demonstrate that chemical 
modification of a previously described Jak2 inhibitor results in the unexpected discovery 
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 Janus kinase 2 (Jak2) is a oncogenic tyrosine kinase that plays a critical role in 
cytokine signal transduction and tumor cell survival. Deregulation of Jak2-dependent 
downstream signaling is common in many forms of cancer. Owing to its crucial role in 
supporting tumor proliferation, Jak2 represents an attractive candidate for targeted 
therapeutics in cancer. This dissertation is focused on studies of a small molecule, 
WP1130, which suppresses Jak2 signaling by a novel mechanism. WP1130 represents 
a second-generation derivative of AG490, a previously described inhibitor of Jak2 
kinase. Although WP1130 resembles AG490 structurally, the inhibition of Jak2 signaling 
by WP1130 is distinct, involving ubiquitination of Jak2. Thorough investigation to gain 
molecular insights into the mechanism of action of WP1130 revealed that WP1130 acts 
a deubiquitinase inhibitor, affecting cellular protein ubiquitination, including Jak2. To 
provide significance to the observations of WP1130’s unique activity, the introductory 
section includes background on both Jak-Stat signaling and the protein-ubiquitination 
pathway. 
A1. Sub-Section: Jak-Stat Signaling 
 
(A1-1) Structure of Jak family proteins 
 Jaks are a family of non-receptor tyrosine kinases containing Jak1, Jak2, Tyk2 
and Jak3 as members. While Jak1, Jak2 and Tyk2 are ubiquitously expressed in all 
tissues, Jak3 is expressed only in hematopoietic cells (1, 2). Structurally, the Jak family 
proteins are characterized by the presence of following domains: an N-terminal FERM 
(four point one, ezrin, radixin, and moesin), central SH2 (src-homology 2), 
pseudokinase and a C-terminal kinase (Illustration 1). The FERM domain of Jak 
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proteins is responsible for their interaction with cytokine/growth-factor receptors (3). Jak 
FERM domain also acts as a chaperone for some cytokine receptors such as EpoR, 
PrlR and oncostatin MR (4), thereby regulating the expression of these receptors. Jaks 
are also characterized by the presence of an N-terminal endogenous SH2 domain. 
Although SH2/SH3 domains are known to play a critical role in mediating protein-protein 
interactions, the role of the SH2 domain in Jak proteins is not yet fully characterized (5). 
A catalytically-active kinase domain is located at the c-terminus of the protein, 
preceding the enzymatically-inactive pseudokinase domain. Although the pseudokinase 
domain lacks any kinase activity, it regulates the overall kinase activity of the Jak 
proteins (6, 7). Recently, many activating mutations within the pseudokinase domain of 
Jak2 have been described which are associated with myeloproliferative disorders (See 
section 1.1D).  
 Owing to their association with cytokine receptors, Jaks are most commonly 
localized to cytokine receptors, as well as the plasma membrane. However, there have 
been reports describing nuclear localization of Jaks (8-10). Nuclear Jak2 has been 
shown to be kinetically active, where it plays a role in stabilization of nuclear factors (8) 
and histone phosphorylation (10). 
 The relevance of signal transduction events mediated by Jak family proteins are 
highlighted in the knockout (KO) phenotype of mice. While Jak1 knockout mice show 
defective lymphoid and neural development(11), the importance of Jak2 in 
hematopoiesis can be illustrated by defective erythropoesis in Jak2-deficient mice, 
leading to embryonic lethality (12, 13). The Jak3 knockout mice revealed an exclusive 
role for Jak3 in maintaining host immunity. A severe reduction in T and B lymphocytes 
and Natural Killer cells is observed in Jak3 KO mice, leading to severe combined 
immune-
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Illustration 1: Domains of Jak proteins and their role in signal transduction.  
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deficiency (14). Although Tyk2 KO mice are phenotypically normal, they show modest 
susceptibility to viral infections (15). 
 
(A1-2) Jak-Stat Signal Transduction  
 Jak2 tyrosine kinase plays a critical role in cytokine signaling in hematopoietic 
cells induced by growth factors such as growth hormone (GH), prolactin (PRL), 
erythropoietin (EPO) and cytokines including IL-3/-5/-6 and interferon (IFN) (16, 17). 
Binding of the cytokines to their cognate receptor leads to receptor homo/hetro-
dimerization, leading to juxtaposition of receptor associated Jak2.  This allows to trans-
phosphorylation of Jak2 within its activation loop [Tyrosine 1007/1008 for Jak2 (18)], 
thereby increasing their catalytic activity. Activated Jak2 in turn phosphorylates critical 
tyrosines on the receptor, creating docking site for latent cytoplasmic proteins which 
relay the downstream signal. One such family of transcription factors is the signal 
transducers and activators of transcription proteins (Stat). Jak2 phosphorylates 
receptor-bound Stats, leading to their dimerization and subsequent translocation to the 
nucleus, where they up regulate the transcription of several genes involved in cellular 
growth, cell cycle as well as anti-apoptotic mechanisms (Illustration 2) [for reviews see 
(19-21)]. Although Stat proteins are key mediators of Jak signalling, they can also be 
activated by other tyrosine kinases such as non-receptor tyrosine kinases including src 
(22), Bcr-Abl (23) or receptor tyrosine kinases such as EGFR (24) and PDGFR (25). 
 The Stat family comprises of seven related proteins – Stat1, Stat2, Stat3, Stat4, 
Stat5a, Stat5b and Stat6 (26). Stats play a dual role in signaling events by acting as 
secondary messengers as well as nuclear factors to relay message from the upstream 
kinase. As nuclear factors, Stats regulate a diverse group of genes, Bcl-xL, cyclin D1, 











Illustration 2: Jak-Stat Signaling. Binding of the cytokine/growth factor to its cognate 
receptor leads to the activation of Jak kinases, which in turn phosphorylate Stat, leading to 
their dimerization. Stats can also be activated independent of Jak, by cytosolic kinases such 
as Abl and Src. Dimers of Stat then translocate to the nucleus, regulating the transcription of 
downstream target genes which play a crucial role in cell growth and survival.   
* Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer 4, 97-105 
(February 2004) 
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(A1-3) Negative-Regulation of the Jak-Stat Pathway  
 Jak-Stat signaling is subject to multiple levels of regulation to prevent excessive 
signalling and abnormal cellular activation that could lead to malignant transformation. 
Stat signaling can be attenuated by several mechanisms including cytokine receptor 
internalization, activation of tyrosine phosphatases, binding of the protein inhibitors of 
activated Stats (PIAS) to Stats and the expression of members of the suppressors of 
cytokine signaling (SOCS) family (Illustration 3).  
Tyrosine Phosphatases:  
 As Jak-Stat signaling is mainly activated via a series of tyrosine phosphorylation 
events, protein tyrosine phosphatases (PTP) play a crucial role in regulating the 
magnitude and duration of the signal. PTPs with reported involvement include SH2-
domain containing tyrosine phosphatases such as SHP1, SHP2; CD45 and PTP1B. 
While SHP1/2 and PTP1B are cytosolic, CD45 is a transmembrane phosphatase. SHP1 
binds to phosphorylated Jak and receptor chains, subsequently dephosphorylating the 
substrate. SHP1 KO mice display hypersensitivity to cytokines such as GM-CSF and IL-
3 (30). Mice deficient in CD45 show hyperactivation of the Jak-Stat pathway and robust 
responses to stimulation from cytokines such as IL-3, IL-4 and EPO (31). PTP1B 
directly binds and dephosphorylates Jak2 and PTP1B KO mice display hypersensitivity 
to leptin activation (32). De-regulations of PTP mediated negative feed-back, such as 
silencing of the shp1 gene by promoter methylation have been reported in various kinds 
of leukemia, lymphomas (33) and myeloma (34).  
Protein Inhibitors of Activated Stats:  
 PIAS are negative regulators of Stat signaling, possessing a small ubiquitin-like 
modifier (SUMO)-E3-ligase activity. They block the transcriptional activity of the Stats, 
without affecting their phosphorylation, by blocking their DNA-binding activity (35) or by 
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recruiting co-repressor proteins such as histone deacetylases (HDAC) (36). 
Additionally, PIAS also promote Stat sumoylation which may inhibit their signaling (37).  
Suppressors of Cytokine Signaling: 
 SOCS proteins are cytokine-inducible negative regulators of Jak-Stat signaling. 
They are distinct from PIAS and PTPs which are constitutively expressed in the cell. 
SOCS proteins inhibit Jak–Stat signalling by competing with Stats for the binding sites 
on the receptor. SOCS also directly bind to Jak and inhibit their activity, which can be 
attributed to the presence of a kinase inhibitory region within their structure. Lastly, 
SOCS suppress Jak-Stat signaling by promoting the ubiquitination and subsequent 
degradation of Jak proteins (38). SOCS1 interacts with a variety of proteins involved in 
the ubiquitin pathway to promote the degradation of Jak [Reviewed in (39)]. SOCS 
proteins also act as tumor-suppressors (40, 41) and the loss of SOCS expression by 
promoter methylation (42) has been associated with tumorogenesis. Recent reports 
also described hyperphosphorylation of SOCS3 in myeloproliferative disorders by 





















Illustration 3: Negative Regulation of Jak-Stat Pathway. Jaks are regulated by both PTPs 
and SOCS proteins. PTPs dephosphorylate activated Jaks; while SOCS promote 
proteasomal degradation of Jaks. Activated Stats are regulated at the level of PTPs and 
PIAS. 
*Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews Immunology 3, 
900-911 (November 2003)] 
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(A1-4) Deregulation of the Jak-Stat pathway in Cancer  
 Given the essential role for Jak-Stat signaling in the growth-promoting activities 
of a number of cytokines, constitutive activation of Jaks would be expected to have 
pathological consequences. The Jak-Stat pathway is often found to be activated in most  
forms of cancer [Reviewed in (44), (45)]. Constitutive activation of Jak2 kinase, either 
through cytokine-autocrine signaling (46) or via formation of Jak2 fusion proteins  has 
been reported to play a role in oncogenesis (47, 48). Additionally, activating mutations 
in Jak2 pseudokinase/kinase domain have been recently implicated in 
myeloproliferative disorders (49, 50). 
 Typically, in oncogenesis associated with Jak2 chromosomal translocation, the 
kinase domain of Jak2 is found to be fused to an amino terminal domain derived from a 
fusion gene which contains a dimerization domain. The resulting fusion protein is 
constitutively active, promoting uncontrolled cell growth even in the absence of any 
cytokine or growth-factor. The first Jak2 chromosomal translocation to be identified 
involved a translocation between Jak2 kinase domain and helix-loop-helix domain of 
TEL (transcription factor). The resulting hyperactive fusion protein, TEL-Jak2 
[t(9;12)(p24;p13)], was demonstrated to play a role in B-cell acute lymphoid leukemia 
and atypical chronic myeloid leukemia (CML) (47), (51). The TEL-Jak2 protein exhibits 
constitutive tyrosine kinase activity and its expression induces transformation of Ba/F3 
cells through IL3-independence (47). Other fusion proteins of Jak2, such as Bcr-Jak2 
[t(9;22)(p24;q11.2)] (52), PCM1-Jak2 [t(8;9)(p22;p240] (48) have also been identified in 
cases of atypical (CML).  
 As described earlier in section A1-1, the pseudokinase domain of Jak2 is 
reported to serve a regulatory role. Therefore, mutations in the pseudokinase domain 
which suppress the auto-inhibitory function of the pseudokinase domain may result in  
 10
Table 1: Fusion proteins/mutations of Jak2 and their implication in cancer. 
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constitutively active Jak2 kinase. The first report describing mutations within Jak2 which 
are associated with a pathological phenotype was reported using Drosophila Jak 
homolog, Hop (53). A point mutation in the pseudokinase domain of Hop was 
associated with a hyperactive Hop kinase and a hematopoietic malignant phenotype in 
flies (54). The relevance of Jak2 mutation in human diseases was further strengthened 
by studies which described short interfering RNA (siRNA)-mediated knock-down of 
Jak2, leading to impaired colony formation in patients with polycythemia vera (PV) (55). 
This observation was later confirmed by several independent groups which reported a 
correlation between a clonal mutation in the Jak2 pseudokinase domain (Jak2 V617F) 
and myeloproliferative disorders, such as essential thrombocytopenia, myelofibrosis 
and PV (49, 50, 56).  Another novel mutation, Jak2T875N, was also identified in acute 
megakaryoblastic leukemia (57).  
 Collectively, the studies mentioned above indicate that the Jak2 chromosomal 
rearrangement and kinase activating point mutations are associated with hematological 
malignancies. These Jak2 gene aberrations in cancer are summarized in Table 1. 
(A1-5) Small molecule inhibitors of Jak2-Stat3 Signaling 
 Many tumors are addicted to oncogenic proteins which play a crucial role in their 
survival. The “addiction” to these oncogenic proteins significantly increases the 
prospects of targeting them for therapeutic purposes. Malignancies such as CML harbor 
the Philadelphia chromosome which is present only in transformed cells and leads to 
the formation of oncogenic Bcr-Abl kinase (58). This observation led to the development 
of small molecules that could disrupt Bcr-Abl kinase activity; thereby sensitizing the 
tumors to apoptosis. However, the human genome codes for nearly 500 kinases, most 
of which possess conserved catalytic domains and ATP-binding pocket. Hence, the 
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generation of small molecule inhibitors which selectively target one or a small subset of 
these kinases without obvious off-target effects seemed challenging. However, the 
development of gleevec for the successful treatment of Bcr-Abl positive-CML (59) has 
provided the proof of principle needed to further develop small molecule inhibitors to 
other oncogenic kinases as well. The epidermal growth factor receptor (EGFR) is 
another receptor tyrosine kinase, which is highly expressed and mutated in cancers 
(60); thereby validating the development of gefitinib and erolotinib, for non-small cell 
lung cancer and pancreatic cancer (61, 62).  
The discovery of gain-of-function Jak2 mutations (V617F) in PV and other 
hematological disorders spurred the interest of the scientific community to develop more 
potent Jak2 inhibitors. Since 2005, many small molecule compounds [TG101348, Z3 
(63), CP-690,550 (64)] have been described to act as Jak2 inhibitors, conferring anti-
tumor activities at low nM concentrations. TG101348 potently inhibits Jak2 tyrosine 
kinase, and suppresses the proliferation of human erythroleukemia cells, which express 
the Jak2-V617F mutation (65), with considerably less off-target effects against related 
kinases, such as Jak3. Treatment of mice expressing Jak2-V617F mutant kinase with 
TG101348 reduced the growth of hemopoietic colonies from primary progenitor cells. 
Currently, the TG101348 compound is undergoing successful phase I/II clinical trials in 
major cancer centers around the world (66). Additional Jak2 inhibitors such as CEP701 
(67) and INCB18424 (68) are undergoing clinical trials.  
Before the development of successful and high affinity Jak2 kinase inhibitors, 
driven by the discovery of kinase activating Jak2 mutation in myeloproliferative 
disorders, Tyrphostin AG490 was the first described inhibitor of Jak2. This compound 
was shown to induce apoptosis in acute lymphoblastic leukemia (69). Although AG490 
displayed anti-tumor properties against many forms of cancer (70, 71), its clinical 
relevance was limited due to lack of specificity (72) and requirements of high μM 
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concentrations for effective Jak2 inhibition. To circumvent this problem, our research 
group screened a small library of AG490 structural analogues for their ability to 
suppress Jak2/Stat3 signaling using cell based assay. Further structure-activity 
relationship (SAR) based screening lead to the design and synthesis of a lead 
compound, WP1130, which could effectively suppress Jak2 driving Stat activation at 
high nM to low μM concentrations. The anti-tumor effects of WP1130 and less active 
derivatives (WP1066, WP1034) against various tumors have already been reported in 
CML (73), melanoma (74), glioblastoma (75) and myeloproliferative disorders (76). An 
earlier report by Ferrajoli et al (77) described down-regulation of Jak2 by WP1066, 
which results in the loss of Stat3 activation and eventually induces apoptosis. Down-
regulation of Jak2 kinase was reported as the mechanism of action of WP1066. 
However, no details of the Jak2 down-regulatory mechanism were provided. 
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A2. Sub-Section: Protein-Ubiquitination Pathway 
(A2-1) Protein Ubiquitination System 
 Post-translational modifications of cellular proteins are induced by a vast variety 
of stimuli and upstream signaling events in cells. Although many different forms of post-
translational modification of proteins have been identified to date, two post-translational 
modifications have emerged as key players in regulating signal transduction pathways. 
These include protein phosphorylation, which involves modification by a phosphate 
group, and protein ubiquitination, involving covalent attachment of ubiquitin to target 
protein. Most often, phosphorylation and ubiquitination precede each other, to regulate 
an individual protein and its cellular activities; suggesting a cross-talk between the two 
post-translational modifications. 
 Ubiquitin is a 76-amino acid protein (~ 8.5 kDa) which is constitutively and 
universally expressed in all eukaryotic cells. Prominent structural features of ubiquitin 
include its C-terminal glycine and the presence of 7 lysine residues. Ubiquitination 
refers to a covalent modification of cellular proteins in which an isopeptide bond links 
the C-terminal glycine of ubiquitin to lysine on the target proteins. The conjugation of 
ubiquitin to target protein involves a complex enzymatic system involving ubiquitin 
activating enzyme (E1), ubiquitin conjugases (E2) and E3 ubiquitin ligases. Although 
protein ubiquitination is known to regulate a myriad of cellular activities, the most 
prominent function of ubiquitin is the labeling proteins for their proteasomal degradation 
[Reviewed in (78)]. Similar to ubiquitin, other ubiquitin-like proteins (UBL) such as 
ISG15, FAT10, NEDD8 and SUMO follow an evolutionary similar evolutionary tract but 
regulate protein functions though distinct enzymatic cascades (79, 80). The known 
























(A2-2) Types of Protein Ubiquitination 
 
Mono/Multi-ubiquitination 
 Proteins that are linked to a single ubiquitin monomer are referred to as mono-
ubiquitinated (Illustration 4A). Similarly, addition of ubiquitin monomers on multiple 
lysine residues of the target protein leads to its multi-ubiquitination or multi-mono-
ubiquitination (Illustration 4B). Monoubiquitination has several regulatory roles for the 
targeted protein, such as inducing changes in subcellular localization, conformation, 
activity and protein interactions (81). However, this type of ubiquitination does not 
control active protein turnover or degradation. Protein monoubiquitination also regulates 
histones and other nuclear proteins in response to DNA-damage (82, 83). Furthermore, 
the elongation of ubiquitin chains on target proteins to form poly-ubiquitinated proteins 
requires mono-ubiquitination to proceed as a priming event (84, 85).  
Polyubiquitination 
 Protein polyubiquitination refers to the sequential addition of many ubiquitin 
monomers to the same protein, thereby forming a chain (Illustration 4C). In contrast to 
monoubiquitination or multi-ubiquitination, polyubiquitination can attribute various 
properties to the target proteins. As stated earlier, ubiquitin has 7 lysine residues, each 
of which can be used to form specific ubiquitin polymers, thereby generating K6-, K11, 
K27-, K29-, K33-, K48- and K63-linked chains on target protein (Illustration 5). In 
addition to the role of K48-linked polyubiquitin chains in regulating protein half-life (78, 
86), various studies have established emerging roles for the K6-, K11, K27-, K29-, K33- 
and K63-linked chains in regulating diverse activities of their target protein. These 
include regulation of DNA repair (87, 88), kinase signaling and activation (89, 90), 






Illustration 4: Types of Ubiquitination.  
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A common mechanism underlying these functions is that ubiquitin, or polyubiquitin 
chains, serves as a signal between ubiquitinated proteins and ubiquitin receptors to 
execute specific biological functions. 
 
K48-Linked Polyubiquitination: It is commonly accepted that formation of K48-linked 
ubiquitin chains tag the protein for proteasome mediated degradation (78, 86).  
Recognition and degradation of ubiquitinated proteins by the proteasome requires 
tetramers or larger oligomers of K48-linked ubiquitin chains on the target proteins (95). 
In this manner, the ubiquitin-proteasome pathway acts as the principal mechanism for 
the turnover of cellular proteins in eukaryotic cells (96). This process leads to protein 
degradation and the recycling of ubiquitin to replenish the cellular pools of monomeric 
ubiquitin by the action of proteasome-associated enzymes, know as deubiquitinases or 
DUBS (97). 
 
K63-Linked Polyubiquitination: A vast number of publications support the non-
degradative role of K63-linked chains. K63-linked polyubiquitination of the transcription 
factor Myc leads to the activation of multiple Myc target genes in tumors (98). K63-
linked ubiquitination also regulates cellular responses to DNA damage (88). 
Ubiquitination of histones following DNA-damage by K63-linked ubiquitin polymers was 
shown to recruit proteins involved in DNA-repair, further strengthening the role of this 
form of ubiquitination in regulating DNA repair. However, the role of K63-ubiquitination 
is best studied in cases of cytokine signaling and receptor endocytosis. Many cell-
surface receptors are K63-ubiquitinated before their internalization and endosomal 
sorting (92-94). Many proteins of the TNF-α receptor complex, such as TRAFs (TNF 
receptor-associated factor), IRAKs (interleukin-1 receptor-associated kinases) and 
components of the TAK [TGFβ (transforming growth factor β)-activated kinase 1] 
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complex, are targets for K63-polyubiquitination (89) (99, 100). The role of K63-
polyubiquitin chains in targeting proteins for proteasomal destruction is not yet fully 
understood. Recent studies have reported the accumulation of both K48- and K63-
linked ubiquitinated proteins after inhibition of the proteasome, suggesting K63-linked 
proteins may also regulate protein degradation (101).  
 
K11- and K29-Linked Polyubiquitination: In addition to K48-linked ubiquitin chains, 
atypical polyubiquitin chains linked by K11- and K29-residues have also been reported 
to degrade tagged proteins. However, these degradation processes are not exclusively 
proteasomal, and also include lysosomal or endoplasmic reticulum-mediated 
















Illustration 5: Role of Lysine-specific polyubiquitin chains. 
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(A2-3) Enzymes of the Ubiquitination Pathway 
(A2-3.1) Ubiquitin Conjugating Enzymes 
Ubiquitin Activating Enzyme (UBE/E1) 
 The transfer of ubiquitin to target protein is mediated in a carefully orchestrated 
three-step reaction, involving initiating with ubiquitin conjugating enzyme. UBE mediates 
the first reaction in the ubiquitin pathway by a two step process involving adenylation 
and thio-ester bond formation. The reaction proceeds with the activation of free ubiquitin 
using its C-terminal glycine in an ATP-dependent process. This adenylation reaction 
leads to the formation of ubiquitin adenylate, with the release of PPi (Illustration 6A, 
Step 1). In the second step, the activated/adenylated- ubiquitin now binds to a cysteine 
residue of E1 forming a covalent-thioester linkage, with the release of AMP (105, 106) 
(Illustration 6A, Step 2). Subsequently, UBE1 catalyses the adenylation of a second 
ubiquitin molecule, thereby getting attached to two distinct ubiquitin molecules; one 
bound by covalent-thioester bond to the catalytic cysteine of the UBE1 enzyme [Ub(T)] 
and another ubiquitin [Ub(A)] which is associated non-covalently (Illustration 6A, Step 
3). A previous study showed that a partially purified UBE1-ubiquitin complex containing 
only the single ubiquitin (T) is capable of transferring the ubiquitin to the next enzyme in 
the ubiquitination cascade (UBE2), this transfer is accelerated by the presence of 
ubiquitin(A) or ATP (107). Until recently, it was believed that there exists a single UBE 
(UBE1) which initiates the ubiquitination pathway. However, recent reports have 
described the presence of a dual ubiquitin charging/activating system, with the 
identification of a new UBE called UBA6 or UBE1L2 (108-110).  
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Ubiquitin Conjugating Enzymes (UBC/E2) and Ubiquitin Ligases (E3) 
 While the human genome encodes for 2 UBE enzymes, it encodes at least 38 
UBCs (111). These enzymes are characterized by the presence of conserved ubiquitin 
conjugating domains and active cysteine residues which are used to interact with UBEs 
(112). The binding of E2 to E1 is facilitated when E1 is charged with activated ubiquitin 
(110). The thioester-linked ubiquitin is transferred from E1 onto the active-site cysteine 
of an ubiquitin-conjugating enzyme by another thioester bond. Though E1/E2 enzymes 
for other UBLs have similar structure to the E1/E2 for ubiquitin, E2s for ubiquitin 
specifically interact with the two E1s of the ubiquitin pathway (110). It is proposed that 
E2s may participate in the recognition of the protein substrate, either directly or in 
combination with an E3 enzyme, thereby providing substrate specificity to the whole 
cascade (78). After being charged with ubiquitin, E2s engage E3 ligases to catalyze 
substrate ubiquitination. Once bound to substrate protein, the E2–E3 pair catalyzes 
ubiquitin chain elongation, during which additional ubiquitin molecules are attached to 
the substrate, leading to its polyubiquitination. The cascade is summarized in Illustration 
6B. 
 Ubiquitin-protein ligases (E3) have central roles in determining the selectivity of 
target protein to be tagged with ubiquitin (78). A single E2 can interact with several 
different E3s. Some of the well known E2–E3 pairs include the yeast Skp–cullin–F-box 
protein (SCF) and the E2 cell division cycle 34 (Cdc34) (113); human anaphase-
promoting complex (APC) and the E2 UBE2C (114); the human TNF receptor-
associated factor 6 (TRAF6) and the heterodimeric E2 UBC13 (89). Though a single E2 




Illustration 6: Protein Ubiquitination Cascade. 
 
(A). Ubiquitin activating enzyme (UBE1) activates ubiquitin using ATP via adenylation. The 
activated ubiquitin is then transferred to the active site of UBE1 and forms a thio-ester bond 
with active cysteine in the pocket. Concurrently, UBE1 activates another uncharged 
ubiquitin, thereby getting double-loaded with two ubiquitin molecules. 
 
(B). The activated ubiquitin is transferred to the ubiquitin conjugating enzyme (E2) at its 
active site. With the help of a ubiquitin ligase (E3), which recruits substrates, E2-E3 
complex transfers the ubiquitin to the substrate. This leads to the dissociation of E2 from 
the E3, allowing it to be recharged with ubiquitin for the next round of transfers. 
 
* Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell 
Biology 10, 755-764 (November 2009) 
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 Since polyubiquitination can be of different types depending on the type of lysine 
being used, formation of specific lysine linked polyubiquitin chains is another intrinsic 
property of many E2s (111). E2 induce changes in the orientation of the acceptor 
ubiquitin in order to expose the preferred lysine to the active site of E2, thereby 
controlling the preference for the formation of specific lysine-linked polyubiquitin chains 
(111, 116, 117).  
 
(A2-3.2) Ubiquitin Deconjugating Enzymes 
 Protein ubiquitination is a two-way process that can be reversed by 
deubiqtuinase enzymes (DUBs). DUBs recognize ubiquitinated proteins and remove 
their ubiquitin tags. Just like ubiquitination which regulates protein function, 
deubiquitination regulates the fate and function of ubiquitin-conjugated proteins. 
Deubiquitinating enzymes are mainly cysteine proteases (with an exception of few 
enzymes), constituting the largest family of enzymes in the ubiquitin system, implying 
their diverse function in the regulation of ubiquitin-mediated pathways. Over 100 
proteins with DUB like activity have been identified (118). Apart from removing ubiquitin 
from protein-ubiquitin conjugates, DUBs also facilitate cleavage of ubiquitin from its 
precursors and unanchored polyubiquitin chains (119). Thus, DUBs regulate and 
maintain the homeostasis of free ubiquitin pools in the cell. Apart from to their active-
site domains, most DUBs also contain additional domains that regulate substrate 
recognition and protein-protein interactions (120).  
 The DUB enzymes are broadly divided into two sub-groups: Ubiquitin C-terminal 
hydrolase (UCH) and the ubiquitin-specific proteases (USP) (119).  USP comprise the 
largest sub-class of DUBs in human, while only 4 known UCH DUBs have been 
described (118). UCH-L1/L2/L3 exhibit tissue specificity in terms of protein expression 
UCH-L1 is localized mainly in brain and testis, while UCH-L3 is present exclusively in 
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brain, lung and hematopoietic cells (121).  DUBs have been shown to be involved in 
numerous cellular processes, such as growth regulation, gene transcription, cell cycle 
control (120-122).  
 
(A2-4) Targeting the ubiquitination pathway for therapeutic 
(i) Proteasome Inhibitors: The ubiquitin system has emerged as the focus of 
molecular targeting in developing novel cancer therapeutics. One of the best 
approaches that have yielded valuable clinical impact is the treatment of multiple 
myeloma and lymphoma patients with proteasome inhibitors. Although alternations in 
proteasomal activities have been seen in multiple diseases, no defects have been seen 
in tumor cells (123). A number of proteasome inhibitors have being developed, such as 
MG-132, lactacystin, epoxymicin (124). However their clinical utilities are limited by 
broad specificity and irreversibility. A boronic-acid derivative, bortezomib (Velcade, 
Millennium Pharmaceuticals), was initially identified in a screening of boronic-acid 
derivatives, to identify potent anti-proliferative agents. Bortezomib inhibited tumor cell 
growth at low nM concentrations (IC50 ~10 nM) (125), reversibly inhibiting the active 
sites in the 20S proteasome (126). Bortezomib-mediated proteasome inhibition 
promotes tumor cell apoptosis a number of mechanisms, including the induction of 
endoplasmic-reticulum stress (127). One of the main mediators of apoptosis induction 
upon proteasome inhibition by bortezomib is the accumulation of p53. The accumulation 
of p53 further stimulates DNA repair, cell cycle arrest and senescence (128, 129). The 
increased accumulation of p53 can further induce the expression of its target genes 
such as p21 and p27, both of which are involved in cell cycle arrest (130). In myeloma 
cells, bortezomib treatment induces activation of the JNK pathway, which activates 
caspase-3 to induce apoptosis (131). Additionally, bortezomib treatment leads to 
release of cytochrome c, resulting in the activation of caspase- 9 (132). Apart from 
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inducing the apoptotic pathway in myeloma cells, bortezomib also blocks the NFkB 
pathway, leading to the suppression of cyclin D1 transcription (133). A summary of key 
signal transduction and cell cycle regulatory pathways that are controlled via 
proteasomal activities is shown in Table 3. The mechanism of action of bortezomib and 
its effect on various cellular processes has been reviewed extensively in (126) (134).  
 Bortezomib is currently used as a first line of therapy to treat patients with 
hematological tumors, such as multiple myeloma and relapsed mantle-cell lymphoma 
(135-137). The success of bortezomib in the treatment of hematological malignancies 
has led to the analyses of bortezomib on solid tumors. Several studies are currently on-
going to investigate the anti-tumor effects of bortezomib in patients with non–small cell 
lung carcinoma (NSCLC), breast cancer, head and neck squamous cell carcinoma 
(HNSCC) and renal cell carcinoma [reviews in (134)]. Although the inhibition of 
proteasome is expected to confer non-specific effects, proteasome inhibitors are novel 
and unique in their mechanism of action that preferentially target transformed tumor 
cells over normal cells (138). Another proteasome inhibitor derived from lactacystin, 
NPI-0052, is currently undergoing clinical trials and is potentially more promising 
because of its oral bio-availability (139). These reports suggest that despite little 
specificity against a component of the ubiquitin system, any perturbations in the 





(ii) Inhibitors of Ubiquitin Conjugating Enzymes (E1/E3): Since E3 ligases bind 
directly to target proteins, they are attractive candidates for developing small molecules 
which disrupt the target protein ubiquitination and thereby its cellular activities. If the 
target protein happens to be an oncogene, any change in its ubiquitination state by 
blocking its specific E3 ligases may activate apoptosis. Well-studied E3 enzymes with 
oncogenic capacity are the RING-type E3 enzyme Hdm2, a crucial negative regulator of 
the tumor-suppressor protein p53, and the multi-subunit SCF ligases that regulate cell-
cycle progression (140-142). Small-molecule inhibitors, such as Nutlins, have been 
generated that specifically target the E3 ligase activity of Hdm2 (143, 144). Treatment 
with these inhibitors has been shown to cause accumulation of p53 (similar to that in 
case with bortezomib), enhancing its signaling activity and inducing apoptosis in a p53-
dependent manner. However, since Nutlins block the interaction between wild-type p53 
and Hdm2, they can only be used in tumors with wild-type p53. Tumor cells with 
mutated or deleted p53 are insensitive to Nutlin induced apoptosis (140). An alternative 
strategy is the development of small molecules which rather bind to the substrate 
protein and prevent the interactions with E3 ligase/s. RITA is a small molecule that has 
been shown to bind the N-terminus of p53 and promote growth arrest (145), that is 
independent of the p53 mutational status. 
 The inhibitors of apoptosis (IAPs) are a family of proteins which confer anti-
apoptotic activity by blocking the proteolytic activity of caspases, thereby promoting cell 
survival. IAPs are often highly expressed in most tumors, and play a critical role in 
metastasis (146). IAPs are RING-domain containing E3-ligases, which regulate their 
own auto-ubiquitination in response to apoptotic stimuli, leading to their proteasomal 
degradation (147). Under normal conditions, the function of IAPs is counteracted by 
mitochondrial proteins called SMAC/DIABLO. By binding to IAPs, SMAC allows 
caspase activation and initiation of apoptosis. Approached to inhibit the activities of 
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IAPs by SMAC mimetics (148, 149) or anti-sense compounds (150) have been shown 
to induce cell death.  
 The role of UBE1 in malignant transformation was recently described by Xu et al 
(151). The authors showed that ubiquitinated proteins content in malignant cells 
compared to normal cell. Using a small molecule compound against UBE1, they 
demonstrated anti-tumor effects in mouse models of leukemia and the induction of ER 
stress. Prior to this, another group had reported the use of an UBE1 inhibitor which 
differentially induced apoptosis in tumor cells (152). These findings demonstrate novel 
mechanisms to induce tumor cell death by inhibiting the UBE1, thereby underscoring its 
importance in tumor cell survival.  
(iii) Inhibitors of Ubiquitin De-conjugating Enzymes (DUBs): DUBs also represent 
appropriate therapeutic targets as several reports have confirmed a role for these 
enzymes in the stabilization of proteins involved in transformation, cell cycle regulation, 
apoptotic protection and drug resistance [reviewed in (120, 122)]. Other studies firmly 
establish a role for DUBs in a broad spectrum of diseases including cancer (153), viral 
and bacterial pathogenesis (154, 155) as well as neurodegenerative disorders (156, 
157). DUBs such as USP1, USP9x, UCH-L1, USP2a and USP44, have been shown to 
play a role in tumor cell survival by regulating key oncoproteins, preventing their 
proteasomal degradation (153, 158, 159). USP1 regulates DNA-repair by inhibiting the 
monoubiquitination of the Fanconi anemia D2 (FANCD2) and proliferating cell nuclear 
antigen (PCNA) (160).  USP9x has been recently shown to be overexpressed in 
multiple myeloma patients, supporting tumor cell survival by preventing proteasomal 
degradation of MCL-1, an anti-apoptotic protein (158). Similarly, USP2a was reported to 
regulate proteasomal degradation of cyclin D1, thereby supporting tumorogenesis 
(159). Another deubiquitinase, USP28,  is overexpressed in colon and breast tumors, 
and causes the stabilization of oncoproteins such as cyclin E1 and c-Myc (161, 162). 
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UCH-L1 has been linked to Parkinson’s disease (163). These observations suggest that 
silencing of specific DUBs in tumor cells may be safe and useful for therapy of 
oncogene addicted cells. Due to the specialized role of DUBs in the ubiquitin cycle and 
their emerging role in control of multiple signaling pathways and oncoproteins, DUB 
inhibitors may be useful anti-cancer agents (164). 
 Peptide based potent, irreversible inhibitors of DUBs, such as ubiquitin aldehyde 
and ubiquitin vinyl sulfone (UbVS) have been previously described (165, 166). 
However, their therapeutic potential is limited by their high mol wt and limited cellular 
bioavailability. The first small molecule reported with anti-DUB activity was D12-
prostaglandin J2, which was initially shown to inhibit cellular DUBs, leading to massive 
accumulation of ubiquitinated proteins (IC50 30 μM). However, the profile of specific 
DUBs affected by this compounds has not yet been described (167). Treatment of lung 
cancer cells with small-molecule inhibitors targeting the UCH-L1 has shown some 
success (168).   
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B. Materials and Methods 
B1. Cell culture, Chemical Reagents and Enzymes 
Human multiple myeloma MM1.S and mantle cell lymphoma Z138 cells were 
grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 
Carlsbad, CA). Adherent cell lines such as human embryonic kidney 293T (HEK293T) 
cells were cultivated on Dulbecco modified essential medium (DMEM) containing 10% 
FBS. All cells were cultured and maintained at 37ºC in a humidified atmosphere. RPMI-
1640 and DMEM were purchased from HyClone (Thermo Fisher Scientific, Waltham, 
MA).  
To establish a Flag-tagged Jak2 overexpressing cell line to study protein-protein 
interactions of Jak2, HEK293 cells were transfected with p3xFLAG-CMV™-10 vector 
containing Flag-Jak2 cloned in-frame with the 3X-Flag peptide (see details below). The 
transfected cells were then grown for 2-weeks in the presence of antibiotic selection 
medium (DMEM + 10% FBS + 1.5 mg/ml G418). The surviving cells were further pooled 
grown to higher density and frozen in liquid nitrogen till use. The expression of Flag-
Jak2 was confirmed by probing the lysates of these cells with either anti-Flag antibody 
or anti-Jak2. Flag-Jak2 overexpressing HEK293 cells were cultures in DMEM, 
supplemented with 10% FBS and G418 (1 mg/ml) at 37ºC in humidified conditions.  
WP1130 and AG490 were provided by Dr. William Bornmann (University of 
Texas, M.D. Anderson Cancer Center, Houston, TX). Other reagents used in this study 
were obtained from the following sources: Bortezomib (Millennium Pharmaceuticals); 
Mini-Complete and PhosSTOP inhibitory cocktails (Roche Applied Science, 
Indianapolis, IN); Ub-AMC, Suc-LLVY-AMC, Boc-LRR-AMC, 20S human proteasome, 
Hemagglutinin-tagged ubiquitin vinyl methyl sulfone (HA-UbVs), UCH-L1, UCH-L3, 
USP5 (BostonBiochem, Cambridge, MA). 
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B2. Plasmids and siRNA transfection 
 cDNA template from MM1.S cells was used to amplify full length human Jak2 
using specific 5’ and 3’ primers containing NotI restriction sites. To generate a Flag-
tagged Jak2 expression plasmid, the amplified Jak2 PCR product was cloned in-frame 
into p3xFLAG-CMV™-10 (Sigma Aldrich, St. Louis, MO). Jak2 was sequenced using 
internal primers to confirm the wild-type status of the cloned product. Expression 
plasmids for HA-tagged ubiquitin (WT/48Only/63Only) were kindly provided by Dr. 
Bryant Darnay (University of Texas, MD Anderson Cancer Center). HEK293T cells 
(105/ml per well) were seeded into 12-well tissue culture plates (~50% confluence). 
Vectors expressing Flag-Jak2 or variants of HA-Ubiquitin were transfected using 
Fugene HD (Roche).  
 ON-TARGETplus siRNA (Thermo-scientific-Dharmacon) for USP9x and USP5 
(30 nM each) were used to knockout USP9x and USP5 in HEK293T cells using 
Lipofectamine 2000 (Invitrogen). Protein levels were estimated after 72 hours of 
transfection by western blotting. 
 
B3. Lysate Preparation, Immunoprecipitation and Western Blotting  
(i) Detergent-Soluble Lysate: To prepare detergent soluble and insoluble fractions, 
cells were lysed in cold isotonic lysis buffer A [10 mM Tris-HCl (pH 7.5), 0.5 % Triton X-
100, 150 mM NaCl along with Mini-Complete and PhosSTOP] for 15 min on ice and 
centrifuged 10 min at 20,000 RCF. The clarified supernatant was used as a source of 
the detergent soluble cell fraction.  
(ii) Detergent-Insoluble Lysate: The residual pellet was sonicated in equal volumes of 





(iii) Whole Cell Lysate: Whole cell lysates were prepared by boiling and sonicating the 
cell pellets in 1x Laemmli reducing sample buffer.  
(iv) Immunoprecipitation: To immunoprecipitate polyubiquitinated Jak2, cells were 
lysed in 100 μL denaturing buffer (1%SDS, 250 mM NaCl) and incubated at 65ºC for 30 
min to disrupt protein-protein interactions. The lysate was sonicated further to dissolve 
proteins in the insoluble pellet into the denaturing buffer (to ensure solubility of the total 
cell lysate).  The lysates were spun at 20,000 RCF for additional 10 mins. The clarified 
supernatant was then diluted by addition of 900 μL lysis buffer A. Immunoprecipitation 
was carried out with either anti-Jak2 or anti-Flag antibody at 4 °C for 2-4 h with rotation, 
followed by overnight incubation with protein-A/G sepharose beads to pull-down 
immune-complexes.  The beads were washed three times in the isotonic buffer and 
boiled in 1x reducing Laemmli buffer. 
(v) Co-Immunoprecipitation: To investigate the association of Jak2 with other proteins 
after WP1130 treatment, co-immunoprecipitation studies were performed. WP1130 
incubation makes Jak2 accumulate in the detergent-insoluble fraction in a time-
dependent manner, making it difficult to immunoprecipitate Jak2 without disrupting 
protein-protein interactions. Therefore, only a brief incubation with WP1130 (1 hr) was 
given in co-immunoprecipitation studies, to allow maximum recovery of Jak2 from the 
detergent-soluble fraction.  Flag-Jak2 HEK293 cells or Z138 cells were either treated 
with WP1130 (5 μM) or DMSO for 1 hour, followed by their lysis in ice-cold lysis buffer 
A. The soluble fraction from these cells was used to immunoprecipitate Jak2 by anti-
Flag or anti-Jak2 antibodies. The association between Jak2 and components of 





Antibodies used in this study were purchased from following sources: anti-actin, 
anti-Flag (Sigma-Aldrich, St. Louis, MO); anti-ubiquitin clone P4D1, anti-HDAC6, anti-
HSP90, anti-20S proteasome, anti-pJak2 (Y1007/1008), anti-Jak2, goat anti-
rabbit/mouse/rat IgG-conjugated horseradish peroxidase (Santa Cruz Biotechnology, 
Santa Cruz, CA); anti-flotillin1, anti-Jak1, anti-Tyk2 (BD Biosciences, San Jose, CA); 
anti-Jak2, anti-pStat3, anti-Stat3, anti-PARP, anti-SOCS1, anti-MCL1 (Cell signaling 
Technology, Danvers, MA); anti-ubiquitin clone FK1 (Enzo Life Sciences International, 
Plymouth Meeting, PA); anti-HA clone 3F10 (Roche Applied Science Indianapolis, IN); 
anti-HDAC6, anti-USP5, anti-USP9x, anti-Jak2 (Bethyl Labs, Montgomery, TX). 
 
B5. 20S Proteasome Activity Assay 
Fluorogenic substrate Suc-LLVY-AMC was used to assay for chymotryptic-like 
activity of the 20S proteasome. To assay for in vivo proteasome inhibition, Z138 cells 
were treated with WP1130 (5 μM) or MG132 (5 μM) for 2 hours. The cells were lysed in 
ice-cold lysis buffer (50 mM HEPES pH 7.5, 5 mM EDTA, 150 mM NaCl & 1% Triton X-
100) and their lysates clarified by centrifugation at 20,000 RCF for 10 min. Equal 
amounts of protein from each sample were then incubated at 37ºC with 100 μM 
fluorogenic substrate.  
To assay for direct inhibition of the 20S proteasome in vitro, purified 20S human 
proteasome (200 ng, Boston Biochem) was incubated with WP1130 (5 μM) and MG132 
(5 μM) for 30 min at 37ºC before addition of the substrates. Fluorescence intensity was 
measured using a spectrophotometer at excitation 360 nm & emission 460 nm. Assays 
were performed in triplicate, and statistical significance was determined with a paired 
Student’s t test. 
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B6. Confocal Microscopy 
 HEK293T cells treated with WP1130 or DMSO for 4 hours were washed twice in 
PBS, followed by fixation using 4% formaldehyde for 15 min. The cells were 
permeabilized in 0.5% Triton X-100 for 5 min. Slides were then incubated in blocking 
solution (5% goat serum) for 1 h at room temperature. Incubation with the primary 
antibodies (1:100) was carried out overnight at 4°C, and the slides were washed three 
times with 0.2% Triton X-100/PBS buffer. Alexa-Fluor anti-mouse and Alexa-Fluor anti-
rabbit immunoglobulin antibodies were used as secondary antibodies. The slides were 
washed three times and stained for nucleus detection with Hoechst 33342. Images 
were acquired using an Olympus FluoView™ 500 (Tokyo, Japan). Images represent 
grouped Z-stacks (Z=0.5 μm) from each sample. 
 
B7. Sub-cellular Fractionation 
 Z138 cells were either treated with 5 µM WP1130 or DMSO for 2 hours, followed 
by their lysis and processing to isolate the cytosolic, membrane, nuclear and 
cytoskeletal fractions. The ProteoExtract Subcellular Proteome Extraction Kit 
(Calbiochem, San Diego, CA) was used to extract each fraction according to the 
manufacturer’s instruction. Markers for each fraction were included to assess the purity 
of each fraction. 
 
B8. In Vitro Deubiquitination Assays 
(i) Ub-AMC Protease Assay: Cells were lysed in ice cold DUB buffer containing 50 mM 
Tris-HCl, pH 7.5, 0.5% NP-40, 5 mM MgCl2, 150 mM NaCl and 1 mM 
phenylmethylsulfonylfluoride. Briefly, 5 µg of clarified lysate from untreated, WP1130 or  
bortezomib treated cells were incubated with 500 nM Ub-AMC in a 100 μl reaction 
volume at 37ºC and the release of AMC fluorescence per minute was recorded. 
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 Purified DUBs at optimal concentrations (USP5; 20 nM, UCH-L1; 20 nM, UCH-
L3; 5 nM, USP9x; immunoprecipitated from 500 μg Z138 cell lysate) were incubated in 
DUB buffer containing WP1130 or DMSO (v/v) in a 100 μl reaction volume for 30 min. 
The reaction was initiated by the addition of 500 nM Ub-AMC and the release of AMC-
fluorescence was recorded at ex/em 380/480 using a spectrofluorometer. 
(ii) Ub Chain Disassembly: In vitro disassembly of purified polyubiquitin chains (K-
48/K-63 linked) was performed as described earlier (169). Five μg of lysate from 
untreated and WP1130 treated Z138 cells prepared in DUB buffer were incubated with 
K48- or K-63 linked chains (1 μg) for 5, 10 and 15 min at 37ºC. The extent of chain 
disassembly was assessed by western blotting. 
 
B9. Deubiquitinase Labeling Assays 
 To assay for changes in activity of cellular deubiquitinase enzymes, Z138 and 
HEK293 cells were lysed in DUB buffer (50 mM Tris pH 7.4, 5 mM MgCl2, 150 mM 
NaCl) for 10 min at 4ºC. The lysates were centrifuged at 20,000 RFC for 10 min and the 
supernatant was used for DUB labeling. Equal amounts of lysate were incubated with 
500 ng of HA-UbVs for 1 hr at room temperature, followed by boiling in reducing sample 
buffer and resolving by SDS-PAGE. After protein transfer to nitrocellulose membranes, 
HA immunoblotting was used to detect DUB labeling. 
 
B10. Measurement of Reactive Oxygen-Species (ROS) 
Z138 cells were treated with DMSO, WP1130 and H2O2 (positive control) for 1 hour. 
The cells were washed with PBS and incubated with H2DCFDA (10 μM) in a CO2 
incubator at 37 °C for 15 min. The DCF fluorescence was measured at 0, 30, 60 and 
120 min, respectively, using with excitation and emission wavelengths of 485 nm and 
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530 nm, respectively. Intracellular ROS accumulation is relative to the fluorescent 
activity of H2DCFDA conversion. 
 
B11. Cell Proliferation/Survival Assessment by MTT 
 Cells were seeded in a 96-well plate at 5,000 cells per well in the presence of 
increasing concentration of WP1130 for 3 days in a CO2 incubator at 37 °C. 20 μl of 5 
g/L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution was 
added to each well for 2 h at 37°C. The cells were then lysed in 10% SDS-buffer and 
absorbance at 570 nm relative to a reference wavelength of 630 nm was determined 
with a microplate reader. The concentrations resulting in 50% inhibition of cell growth 
(IC50 values) were calculated. 
B12. Statistical analysis 
 A statistical analysis was performed using two-tailed Student's t-test to assess 
the statistical significance of treated groups versus control groups. The results with P-





C1. Small-Molecule Inhibitors of the Jak2/Stat3 Pathway  
 Using cell based screening assays, we screened a small chemical library (>200) 
of AG490 structural analogues to identify more potent antagonists of the Jak2/Stat3 
pathway.  This approach involved incubation (2 hr) of MM1.S cells with the test 
compound, followed by a brief IL-6 (15 min) stimulation to activate the Jak2/Stat3 
cascade. Potency of the compounds was then judged by comparing the levels of pStat3 
in IL-6 stimulated cells against the cells pre-treated with the inhibitor. As shown in 
Figure 1 (upper panel), initial studies led to the identification of more effective AG490 
derivatives (AG1801, AG2019), which suppressed Stat3 activation at lower μM 
concentrations (12-25 μM). A second round of screening using AG1801 analogues led 
to the identification of WP compounds; namely WP1066, WP1129 and WP1130. These 
2nd generation AG490 derivatives displayed even more potent inhibitory activities 
against the Jak2/Stat3 pathway (Figure 1, lower panel).   
 We found WP1130 to be the most potent analogue among the newer 
derivatives, completely suppressing IL-6 driven phosphorylation of Stat3 at much lower 
doses (2.5-5 μM) than AG490 itself (Figure 2A). However, WP1130 showed no 
inhibition of Jak2 autophosphorylation in an in-vitro kinase assay even at higher μM 
concentrations (Figure 2B). These results suggest that in contrast to its parental 
tyrphostin AG490, WP1130 potently inhibits Jak2 driven signaling without directly 
affecting its kinase activity. 
 
  39
Figure 1. Development of potent inhibitors of Jak-Stat signaling 
Cell based assay were used to identify AG490 derivatives which effectively suppress 
IL-6 stimulated Stat3 activation. MM1s cells were pre-treated for two hours with the 
indicated concentration of first (AG1801, 2019) and second generation (WP1066, 
1130) AG490 analogues, followed by a brief IL-6 stimulation (10 ng/ml, 15 min). The 
extent of suppression of Jak-Stat signaling was assessed by monitoring the 























Figure 2. Inhibition of Jak2-Stat3 signaling by WP1130 
 
(A). MM1s cells were treated with indicated concentration of WP1130 or AG490 for two 
hours and stimulated with IL-6 to activate Jak2-Stat3 signaling. WP1130 effectively 
suppresses Stat3 activation at low μM concentration compared to AG490. 
 
(B). Purified Jak2 was incubated in the presence of WP1130 or AG490 for 2 hours in 
kinase buffer. The autophosphorylation of Jak2 was assessed by incubation in labeling 
reagent consisting of 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.1 mM Na2VO4, and 5 μCi 
32P-ATP. After 30 min at room temperature, proteins were resolved by SDS-PAGE and 
phosphorylation detected by autoradiography. 
A. B. 
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C2. Anti-Tumor Properties of WP1130 
 Our preliminary studies showed that mantle cell lymphoma Z138 and multiple 
myeloma MM1s cells displayed high apoptotic sensitivity to WP1130 (IC50 ~1 µM). 
WP1130 effectively suppressed the growth of various other cancer cell lines of lymphoid 
and myeloid origin at low μM concentration (Figure 3A).  Treatment of Z138 cells with 
WP1130 induced rapid apoptosis, evident by the appearance of cleaved PARP after 2-4 
hours of treatment. Direct comparison of WP1130 with AG490 or bortezomib, which is 
clinically active in mantle cell tumors, illustrated distinctions in the apoptotic onset and 
activity of each compound (Figure 3B). Similar results were observed in MM1s and 
HEK293 cells, suggesting WP1130 has potent anti-tumor properties (Figure 3C). The 
anti-proliferative and apoptotic effects of WP1130 and less active derivatives (WP1066, 
WP1034) against various tumors have recently been reported in CML (73), melanoma 
(74), glioblastoma (75) and myeloproliferative disorders (76). 
 
C3. Suppression of Jak2 Signaling by WP1130 
 Since we observed potent inhibition of Jak2/Stat3 signaling by WP1130 in the 
absence of Jak2 kinase inhibition, we investigated the mechanism of WP1130-mediated 
suppression of the Jak2-Stat3 pathway. We immunoprecipitated Jak2 from the soluble 
extracts of DMSO, IL-6 and WP1130/IL-6 treated MM1.S cells. Immunoblotting with ant-
phosphotyrosine revealed that WP1130 pre-treatment inhibited IL-6 driven Jak2’s 
phosphorylation. Interestingly, probing the same membrane for Jak2 showed a decline 
in Jak2 levels in WP1130 treated cells (Figure 4). The observed down-regulation of 
Jak2 in WP1130 treated cells was an unexpected result. Loss of Jak2 protein by 


























Figure 3. Anti-proliferative effects and induction of apoptosis by WP1130 in various 
cell lines of lymphoid and myeloid origin. 
 
(A). IC50 values of WP1130 in various cell lines; CML= chronic myelogenous leukemia, 
ALL= acute lymphocytic leukemia, MPD= myeloproliferative disorders, NB= normal B-cells, 
NM= normal myeloid cells. 
 
(B). Mantle cell lymphoma (Z138) cells were treated with WP1130 (5 μM), AG490 (100 μM) 
or Bortezomib (50 nM) for the interval indicated. Whole cell extracts were probed for 
detection of cleaved PARP as an indicator for onset of apoptosis. Actin was probed on the 
same blot as a protein loading control. 
 
(C). MM.1S and HEK293T cells were treated with 5 μM WP1130 for the indicated intervals. 
Whole cell extracts were probed for detection of cleaved PARP as an indicator for the 






 To investigate whether AG490 has similar effects on Jak2 protein levels, we 
treated MM1.S cells with DMSO, WP1130 (5 μM) or AG490 (50 μM) for 2 hours, 
followed by their lysis. Jak2 was immunoprecipitated from soluble lysates and subjected 
to immunoblotting. We noted that Jak2 down-regulation was a unique characteristic of 
WP1130, which was not exhibited by AG490 (Figure 5A), suggesting different 
mechanisms for inhibition of Jak2-Stat3 signaling. To further examine the kinetics of 
WP1130 mediated Jak2 down-regulation, we treated MM1.S cells with 5 μM WP1130 
for 30, 60 and 120 min. The cells were then briefly stimulated with IL-6 to activate Jak2-
Stat3 signaling. Shorter intervals of incubation of MM1.S cells with 5 μM WP1130 (30 
min-120 min) showed a rapid, time dependent, loss of Jak2 protein from cell lysates 
(Figure 5B). The decline in Jak2 protein levels paralleled the loss of downstream Stat3 
activation upon IL-6 stimulation; however, no decline in Stat3 protein was observed 
(Figure 5B). These results show that WP1130 induces down-regulation/degradation of 
Jak2, leading to the suppression of downstream Stat3 signaling. These results are 
aligned with previous reports regarding Jak2 down-regulation in cells treated with 
WP1130 and the related compound WP1066 (73, 76, 77). 
 We next examined whether a proteolytic pathway was activated by WP1130 to 
induce Jak2 down-regulation. We assessed inhibitors of the proteasomal [MG-132] and 
other proteolytic pathways [lysosomes (NH4Cl), cysteine proteases (E64D), 
papain/trypsin (Antipain), chymotrypsin (TPCK)] for their ability to suppress WP1130 
mediated Jak2 down-regulation.  MM1s cells were incubated with effective 
concentrations of each proteolytic inhibitor for 1 hr, prior to treatment with 5 μM 
WP1130 for additional 2 hours. The cells were then stimulated with IL-6 to activate the 
Jak2 signaling cascade. We observed no inhibition of WP1130-mediated Jak2 down-
regulation in the presence of any of these protease inhibitors (Figure 6), and Stat3 
phosphorylation remained suppressed by WP1130.  
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Figure 4. WP1130 induces rapid down-regulation of Jak2   
MM1s cells were treated with WP1130 (5 μM) for 2 hours, followed by brief IL-6 stimulation. 
Untreated or IL-6 alone treated cells served as controls. Jak2 was immunoprecipitated from 
the lysates (supernatant) and probed for its phosphorylation and residual protein levels 
using anti-phosphotyrosine (4G10) and anti-Jak2 antibody. WP1130 treatment inhibits Jak2 
phosphorylation by decreasing its protein levels. A fraction of the lysate (input) from these 
cells was also probed to confirm the inhibition of Stat3 activation by WP1130. No loss in 
Stat3 protein levels was detected upon WP1130 treatment. 
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Figure 5. Kinetics of WP1130 mediated down-regulation of Jak2   
 
(A). MM1s cells were treated with WP1130 (5 μM) or AG490 (100 μM) for two hours and 
stimulated with IL-6. The supernatant lysates were used to detect changes in Jak2 protein 
levels upon WP1130 and AG490 treatment. While WP1130 effectively suppressed Stat3 
activation through potent Jak2 down-regulation, AG490 had no affect on Jak2 protein 
levels. Untreated or IL-6 alone stimulated cells served as controls. Stat3 was blotting was 
used as protein loading control.   
 
(B). MM1.S cells were incubated with 5 μM WP1130 for the indicated time interval, 
followed by IL-6 stimulation. The lysates were probed to assess the kinetics of Jak2 down-





























Figure 6. Effect of protease inhibitors on WP1130-induced Jak2 down-regulation. 
 
Inhibitors of various proteolytic pathways were used to prevent WP1130 induced Jak2 
down-regulation. MM1s cells were pretreated with MG-132 (5 μM), NH4Cl (10 mM), 
Antipain, E64D and TPCK for 1 hour. The cells were then further incubated with WP1130 
(5 μM) for an additional 2 hour, followed by IL-6 stimulation. The lysates were probed for 
any inhibition in the loss of Jak2 and the restoration of Stat3 signaling in the presence of 




C4. WP1130 Mediated Trafficking of Jak2  
 To investigate potential accumulation of Jak2 into other cellular fractions that are 
not solublized by standard extraction conditions, we modified our lysate extraction 
protocol to investigate the possible accumulation of Jak2 into the detergent insoluble 
cell fraction (see materials and method).  Examination of the detergent-soluble extracts 
(soluble) of WP1130 treated Z138 cells demonstrated a rapid loss of Jak2 protein, as 
noted in earlier experiments. However, we observed a subsequent time-dependent 
increase in Jak2 levels in the detergent-insoluble fraction (insoluble) of the cell, with no 
apparent decline in Jak2 protein from total cell extracts (Figure 7A). Careful examination 
of the lysate preparation protocols of earlier reports describing Jak2 down-regulation 
(73, 76) by WP1130/WP1066 revealed the use of soluble supernatants as the source of 
lysate. Our results show that WP1130 treatment induces re-localization of Jak2 into the 
insoluble fraction, without inducing its degradation. These results are consistent with our 
protease/proteasomal inhibitor studies which failed to block the loss of Jak2 protein in 
WP1130 treated cells.  
 Among the Jak family proteins, Jak2 was found to be the most sensitive to 
WP1130 treatment. Treatment of Z138 cells with 5 μM WP1130 for 2 hours showed 
very little impact on the accumulation of Tyk2 and Jak1 in the insoluble fraction (Figure 
7B); consistent with a previous report where WP1066 showed no change in their protein 
levels (77). Cytokine receptor was also not affected by WP1130 as no accumulation of 
gp130 was seen in the insoluble fraction of WP1130 treated Z138 cells. Furthermore, 
treatment of Flag-Jak2 overexpressing HEK293 cells with WP1130 showed a similar 
accumulation of Flag-tagged Jak2 in the detergent insoluble fraction following WP1130 































Figure 7. Effects of WP1130 on trafficking of Jak2 and Jak-family members.   
 
(A). Z138 cells were treated with 5 μM WP1130 for indicated time period. The cells were 
then processed to extract their detergent-soluble, detergent-insoluble or total cell lysate as 
described in the materials and methods. The presence of Jak2 in each fraction was 
assayed by immunoblotting with anti-Jak2 antibody.    
 
(B). Z138 cells were treated with DMSO (-) or WP1130 (+) and their soluble and insoluble 
fractions were analyzed to assess the specificity of WP1130 towards other Jak family 
members (Jak1, Tyk2) and gp130. Actin was used as a loading control. 
 
(C). Flag-Jak2 overexpressing HEK293 cells were treated with WP1130 (+) or DMSO (-) for 
2 hours, followed by the extraction of soluble and insoluble lysates. The lysates were 





- - - - ++++
ISOTONIC LYSIS
0.5% TX-100, 150 mM NaCl
HYPERTONIC LYSIS
0.5% TX-100, 0.1% SDS, 300 mM NaCl
Jak2
Actin
Figure 7. Effects of WP1130 on trafficking of Jak2 and Jak-family members 
(continued).   
 
(D). Z138 cells were treated with DMSO (-) or WP1130 (+) for 2 hours. The cells were then 
split and lysed under isotonic conditions or hypertonic/stringent conditions. The detergent-
soluble and –insoluble lysates obtained from each lysis condition were then probed for the 




 Furthermore, the accumulation of Jak2 in the detergent-insoluble fraction of 
WP1130 treated cells was seen under both isotonic/mild and hypertonic/stringent lysis 
conditions (Figure 7D). This suggested that the observed accumulation of Jak2 in the 
insoluble fractions of WP1130 treated cells is not merely due to inefficient extraction of 
the cellular lysates. 
   
C5. Effect of WP1130 on the Accumulation of Ubiquitinated Proteins  
 Molecular analysis revealed some structural and chemical similarities between 
WP1130 and a few compounds with described DUB inhibitory activity, such as 
dibenzylideneacetone (DBA) and curcumin (167). These observations prompted a 
detailed analysis of affects of WP1130 on cellular protein ubiquitination. Since 
ubiquitination has been reported to regulate protein accumulation in the detergent-
insoluble fraction (170), we examined whether WP1130 affected ubiquitination of 
cellular proteins, leading to their accumulation in the insoluble fraction. We treated Z138 
cells with WP1130, AG490 or bortezomib and probed the detergent-soluble and –
insoluble cell fraction for the presence of ubiquitinated proteins. We observed a massive 
increase in the presence of polyubiquitinated proteins in WP1130 treated cells, 
resembling bortezomib treatment. However, the increased accumulation of ubiquitinated 
proteins in the insoluble fraction of WP1130 treated cells was markedly distinct from 
that of bortezomib treatment (Figure 8A). Additionally, only WP1130 treatment induced 
Jak2 to accumulate in the insoluble fraction. No changes in either cellular ubiquitinated 
protein levels or in the distribution of Jak2 were observed in AG490 treated cells. 
Although Bortezomib treatment led to the accumulation of ubiquitinated proteins in the 
soluble fraction, no such accumulation was observed in the detergent-insoluble fraction. 
We further analyzed whole cell extracts (WCE) from WP1130 treated Z138 cells and 
observed a marked and concentration-dependent accumulation of ubiquitinated proteins 
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Figure 8. Effects of WP1130, Bortezomib and AG490 on protein ubiquitination and 
trafficking. 
 
(A). Z138 cells were treated with 5 μM WP1130, 50 nM bortezomib or 100 μM AG490 for 2 
hours and their lysates were resolved into a detergent-soluble and –insoluble fraction. 
Changes in the distribution of Jak2 and ubiquitinated proteins by each compound were 
assessed by western blotting. Actin blotting served as protein loading control. 
 
(B). Z138 cells were incubated with the indicated concentration of WP1130 for 2 hrs before 
whole cell lysates were subjected to immunoblotting with anti-ubiquitin. Membranes were 
probed for actin as a protein loading control. 
 
 
Total Cell Lysate 
A. B.
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(Figure 8B). A similar increase in protein ubiquitination was seen in other WP1130 
treated cells including K562, MM.1S, HeLa and HEK293 (data not shown). These 
results suggest distinctions in the molecular mechanism of WP1130 compared to the 
proteasome inhibitor bortezomib and AG490.  
 
C6. WP1130 Does Not Act as a Proteasome Inhibitor 
 To further differentiate between bortezomib and WP1130, we examined the 
kinetics of accumulation of ubiquitinated proteins into the detergent-soluble and –
insoluble fraction. We observed a time-dependent accumulation of ubiquitinated 
proteins into both the detergent soluble and insoluble fraction of Z138 cells upon 
treatment with WP1130. Bortezomib (50 nM) did not induce significant accumulation of 
insoluble ubiquitinated proteins, with only minimal ubiquitin content change in the 
detergent insoluble fraction even after 8 hours of treatment (Figure 9A). The 
accumulation of ubiquitinated proteins can occur following proteasome inhibition. 
Therefore, we next examined whether WP1130 had any affects on 20S proteasome 
activity in treated cells or against the purified 20S proteasome. As shown in Figure 9B, 
WP1130 incubation (5 µM, 2 hr) caused no significant decline in proteasome 
chymotryptic-like activity in vivo (p-value > 0.07) and in vitro (p-value > 0.78) while MG-









Figure 9. Differential effects of WP1130 and Bortezomib on protein ubiquitination.  
 
(A). Z138 cells were treated with either WP1130 or Bortezomib for the interval indicated. 
Lysates were separated into detergent soluble and insoluble fractions as described in the 
materials and methods and probed for the distribution of ubiquitinated proteins and actin as 
a protein loading control by immunoblotting.  
 
(B). Left (In vivo)- Lysates from DMSO (control), WP1130 or MG-132 treated cells (5 μM, 
2 hr) were analyzed for proteasome activity as described the material and methods.  Right 
(In vitro) - Purified 20S proteasome was incubated with 5 μM WP1130, 5 μM MG-132 or 
DMSO for 30 min before analysis of chymotryptic or tryptic proteasome activities by 






C7. WP1130 Induces Trafficking of Jak2 into Aggresomes  
 Insoluble, ubiquitinated proteins have been previously shown to accumulate in 
structures called aggresomes (171, 172). Aggresomes, often characterized by the 
presence of multiple marker proteins such as HDAC6, 20S Proteasome, HSP90/70 
along with ubiquitinated proteins, are distinct in their peri-nuclear localization (173, 174). 
Ubiquitinated proteins are transported to the aggresome by HDAC6 using dynein 
motors via the microtubule network (175). To further define the Jak2 enriched insoluble 
fraction, we performed sub-cellular fractionation of WP1130 treated Z138 cells. 
Following WP1130 treatment, Jak2 was predominantly detected in the cellular 
cytoskeletal fraction, along with other markers of aggresomes (Figure 10A). To validate 
the association of Jak2 with the aggresomal machinery consisting of HDAC6, HSP90 
and CHIP, we performed co-immunoprecipitation studies. Z138 cells were treated with 
WP1130 for 30 min to induce Jak2 ubiquitination and facilitate further protein-protein 
interaction. The detergent-soluble fraction obtained from these cells was used to pull-
down Jak2 and probe for associated aggresomal proteins. As shown in Figure 10B, 
increased association between Jak2, HSP90, CHIP and HDAC6 was noted following 
brief WP1130 treatment, suggesting ubiquitinated Jak2 was affiliated with aggresome-
marker proteins. We further performed confocal microscopy of HEK293 cells treated 
with DMSO or WP1130 for 2 hours to firmly establish localization of Jak2 in peri-nuclear 
aggresomes. As shown in Figures 11, we observed accumulation of HDAC6 in dense, 
compact regions outside the nucleus, co-localizing with ubiquitinated proteins, a 
hallmark of aggresome formation. We also observed co-localization between 
ubiquitinated proteins and 20S proteasome (Figure 12) or Jak2 (Figure 13). 
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Figure 10. Accumulation of Jak2 in cellular cytoskeletal/Aggresomal fraction.  
 
(A). Z138 cell were treated with DMSO (-) or 5 μM WP1130 (+) for 2 hrs before cell extracts 
were subjected to fractionation into cytoplasmic (F1), membrane-associated (F2), nuclear 
(F3) of cytoskeletal (F4) components. Equal protein content was subjected to 
immunoblotting for ubiquitin (top) or markers for each fraction. The cytoskeletal fraction 
from WP1130 treated cells was highly enriched with ubiquitinated proteins as well as Jak2 


















































Figure 10. Accumulation of Jak2 in the cytoskeletal/aggresomal cell fraction.  
 
(B). Z138 cell were treated with DMSO (-) or 5 μM WP1130 (+) for 1 hr before lysis in 
isotonic lysis buffer. Jak2 was immunoprecipitated as described in the materials and 

















C8. Polyubiquitination of Jak2 by WP1130  
 Considering the effect of WP1130 on protein ubiquitination, we investigated 
whether Jak2 undergoes ubiquitination in response to WP1130. Since WP1130 
treatment renders Jak2 in-extractable, we used denaturing conditions to 
immunoprecipitate Jak2 to detect its ubiquitination (see materials and methods). 
Through this approach we detected rapid ubiquitination of Jak2 following WP1130 
treatment. Similar results were obtained in HEK293 cells over-expressing Flag-tagged 
Jak2 (Figure 14A). Proteasome inhibitor MG-132 was used as a positive control to allow 
accumulation of endogenously ubiquitinated Jak2. The presence of ubiquitinated Jak2 
in WP1130 treated cells was novel and in contrast to it’s previously described mode of 
ubiquitination which is dependent on cytokine stimulation (38). Additionally, to 
differentiate between poly-ubiquitinated Jak2 and its multi-ubiquitinated forms, we used 
a monoclonal anti-ubiquitin antibody (FK1) that specifically recognizes only poly-
ubiquitinated proteins and not their mono-/multi-ubiquitinated forms (81). 
Immunoblotting with FK1-anti-ubiqutin confirmed the polyubiquitination of Jak2 after 
WP1130 treatment (Figure 14B). 
 To further investigate the type of polyubiquitin linkage formed on Jak2 after 
WP1130 treatment, we used HA-tagged variants of ubiquitin. The ubiquitin variants can 
either use any available lysine on ubiquitin (WT), or use Lysine-48 only (K48O) or 
Lysine-63 only (K63O) to form polyubiquitin chains. Flag-Jak2 HEK293 cells were 
transfected with each HA-Ub variant expression plasmid. Following 2 days of 
transfection, the cells were then treated with 5 μM WP1130 for 1 hour, followed by their 
lysis to immunoprecipitate Jak2 with anti-Flag antibody. Immunoblotting with HA 
showed the presence of ubiquitinated Jak2 after WP1130 incubation in cells transfected 
with either WT or K63O variants of HA-ubiquitin. No accumulation of polyubiquitinated 





























Figure 14. WP1130 induced ubiquitination of Jak2.   
 
(A). Z138 or HEK293 Flag-Jak2 cells were treated with WP1130 (5 μM) or MG-132 (5 μM) 
for 1 hours and lysed under denaturing conditions to immunoprecipitate ubiquitinated Jak2 
(as described in materials and methods).  
 
(B). Ubiquitination of Jak2 was probed using 2 different anti-ubiquitin antibodies – P4D1 
(detects mono-/multi-/poly-ubiquitinated proteins) and FK1 (detects polyubiquitinated 
proteins only).  
Jak2-Ub(n)Jak2-Ub(n)
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Figure 15. Ubiquitination of Jak2 using K63-Linked polyubiquitin chains   
 
Flag-Jak2 HEK293 cells were transfected with vectors expressing either WT or mutated 
variants (lysine 63 only/lysine 48 only) of HA-tagged ubiquitin. After 2 days of transfection, 
the cells were treated with WP1130 (5 μM) for 1 hour and Jak2 was immunoprecipitated 












C9. WP1130 acts as Deubiquitinase Enzyme Inhibitor  
Inhibition of cellular deubiquitinases could lead to an increase in high molecular 
weight ubiquitinated proteins in the absence of proteasome inhibition (176, 177). As 
described earlier, WP1130 shares some structural and chemical resemblance to known 
DUB inhibitors. Therefore, we assessed possible indications of DUB inhibition in 
WP1130 treated cells. We observed a rapid depletion of monomeric ubiquitin (Figure 
16A) and a subsequent increase in the levels of unanchored/free polyubiquitin chains 
(Ub4-5) in cells treated with WP1130 (Figure 16B). In contrast, bortezomib treatment did 
not affect the level of free ubiquitin or unanchored ubiquitin chains. This observation 
suggests that WP1130 may reduce ubiquitin recycling and amass ubiquitinated proteins 
through inhibition of deubiquitinase activity. To directly assess the impact of WP1130 on 
DUB activity in treated cells, cell lysates from control and treated cells were incubated 
with ubiquitin-AMC and fluorescence generated as a consequence of substrate 
cleavage was measured as an indicator of DUB activity. Treatment with WP1130 
significantly reduced DUB activity by nearly 50% by 4 hours (p- value 0.0095). 
Interestingly, we did not see any change in DUB activity in bortezomib treated cells 
(Figure 16C).  
We also examined the effect of WP1130 treatment on in vitro 
deubiquitination/disassembly of purified K48-linked or K63-linked polyubiquitin chains. 
Lysates from WP1130 treated (2 hr) or untreated cells were incubated with 1 μg of 
unanchored polyubiquitin chains for 5, 10 and 15 min at 37ºC.  Lysates from untreated 
cells caused an almost complete disassembly of polyubiquitin chains in contrast to the 
limited disassembly observed with lysates from WP1130 treated cells (Figure 16D). 
Lack of chain disassembly of both K48- and K63-linked polyubiquitin chains from the 
lysates of WP1130 treated cells is in agreement with our previous observations of 
increased accumulation of both types of ubiquitin linkages upon WP1130 treatment 
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Figure 16. WP1130 reduces cellular deubiquitinating activity. 
 
(A). Z138 cells were incubated with DMSO, WP1130 (5 μM) or bortezomib (50 nM) for the 
indicated intervals. Whole cell extracts were probed for the levels of mono-ubiquitin by 
running high percent (15%) gels. 
 
(B). Z138 cells were treated with DMSO (Control), 5 μM WP1130 or 50 nM bortezomib for 
2 hrs before whole cell lysates were resolved on high percent cross-linked gels and 
subjected to immunoblotting for ubiquitin and actin. Preformed ubiquitin polymers (Ub1-7) 




Figure 16. WP1130 reduces cellular deubiquitinating activity (continued). 
 
(C). Z138 cells were treated with 5 μM WP1130, 50 nM bortezomib or DMSO for the 
interval indicated before extracts (5 μg) were prepared as described in the materials and 
methods and incubated with fluorogenic substrate. The results are representative of one 
analysis performed in triplicate. Similar results were obtained in two additional independent 
assays. 
 
(D). Lysates (5 μg) from vehicle treated (DMSO) or WP1130 treated (5 μM, 4 hrs) cells 
were incubated with 1 μg of K-48 linked (left) or K-63 linked (right) free chains of 
polyubiquitin (Ub1-7) for 5, 10 and 15 min at 37ºC. The extent of free chain hydrolysis in 






(Figure 16D). These results suggest that WP1130 treatment inhibits cellular DUB 
enzyme/s required for the breakdown of both K48- and K63- specific ubiquitin linkages. 
 
C10. DUB Inhibitory Profile of WP1130 
 To further assess DUB inhibition in WP1130 treated cells, we employed a 
technique described by Borodovsky et al (166, 178) to identify the profile of active 
cellular DUB activity in intact cells. Hemagglutinin-tagged ubiquitin vinyl methyl sulfone 
(HA-UbVs) acts as a DUB suicide substrate, forming a covalent adduct with active DUB 
enzymes. Specific cellular DUBs can be identified by anti-HA blotting, as previously 
shown in various cell types (178-180). Changes in specific DUB activities are 
measurable by monitoring HA-labeling in lysates from control and treated cells. A dose-
dependent and time reduction in the labeling of DUBs corresponding to USP9x, USP5, 
USP14 and UCH37 was seen in cells treated with WP1130 (Figure 17A, 17B). In 
contrast, no change in DUB labeling was noted in cells treated with AG490, confirming 
distinctions in the activity and mechanism of action of the parental tyrphostin and 
WP1130. An in vitro analysis using cell lysates was performed to investigate direct DUB 
inhibition by WP1130. Briefly, untreated Z138 lysates were incubated with 5 µM 
WP1130 or DMSO for one hour at 37ºC, followed by labeling with HA-UbVs. Incubation 
of cell lysate with WP1130 showed a reduction of HA-labeling of the same DUBs as 
those noted in intact cells (Figure 17C), suggesting that WP1130 caused direct DUB 
inhibition.  
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Figure 17: DUB inhibitory profile of WP1130. 
 
(A). Z138 cells were treated with the indicated concentration of WP1130 or AG490 (250 μM) 
for 1 hours. The cells were lysed in DUB labeling buffer as described in the materials and 
methods. 20 μg of clarified supernatant was incubated with 200 nM of HA-UbVS for 1 hr at 
37ºC. HA immunoblotting was used to assess changes in DUB labeling. Actin was probed as 
a protein loading control. Dual exposures are shown to allow determination of DUB inhibition 
against DUBs with high and low labeling activity. Individual DUBs were assigned (right) 





Figure 17: DUB inhibitory profile of WP1130 (continued). 
 
(B). Z138 cells were treated with 5 μM WP1130 for the interval indicated followed by lysis in 
DUB buffer. Lysates were subjected to HA labeling and DUB assignments were made based 
on the criterion described in A.   
 
(C). Untreated Z138 cell extracts were prepared in DUB buffer as described in the materials 
and methods. 20 ug of lysate were incubated with DMSO or 5 μM WP1130 for 1 hr at 37ºC. 
The reaction mixture was subjected to labeling with 200 nM HA-UbVS for an additional 1 hr 
at 37ºC and DUB activity was assessed by HA immunoblotting.  
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C11. Direct Inhibition of DUBs by WP1130  
 To determine whether WP1130 directly inhibits DUB activity, we incubated 
purified DUBs such as USP5, UCH-L1 and UCH-L3 with DMSO and WP1130 for 30 min 
in DUB buffer at 37ºC. USP9x was immunoprecipitated from Z138 cell lysates, prepared 
in DUB buffer and the beads were incubated with DMSO or WP1130 for 30 min. Ub-
AMC (500 nM) was added to each reaction and fluorescence was monitored every 
minute for up to 30 minutes. The maximum fluorescence observed at the end of the 
linear phase of substrate cleavage in DMSO or WP1130 treated DUBs was used as a 
gauge to estimate DUB activity and % inhibition. As shown in Figure 18A, treatment 
with 5 μM WP1130 reduced the activities of USP9x, USP5 and UCH-L1 by 60 % or 
more (detail in 18C). No inhibition was observed against UCH-L3 activity, suggesting 
that WP1130 may be partly selective. We confirmed the loss of USP5 activity using HA-
UbVs labeling, which demonstrated ~80% reduction in HA labeling upon incubation with 
WP1130 (Figure 18B). 
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Figure 18: WP1130 inhibits purified deubiquitinases. 
 
(A). Optimal concentrations of recombinant or immuno-purified deubiquitinase enzyme 
(USP5; 20 nM, UCH-L1; 20 nM, UCH-L3; 5 nM, USP 9x; immuno-isolated) were incubated in 
DUB activity buffer containing WP1130 or DMSO (v/v) in a 100 μl reaction volume for 30 min 
at 37ºC in 96-well fluorometry plates. After incubation, 500 nM Ub-AMC was added to the 
reaction and the release of AMC-fluorescence was recorded over time. The % activity for 
each enzyme was estimated by monitoring the change in substrate cleavage relative to 
DMSO treatment (representing 100% activity). 
 
(B.) Recombinant USP5 (20 nM) was subjected to HA-UbVs labeling in the presence of 
DMSO or 5 μM WP1130 (30 min). Immunoblotting was used to determine USP5 activity (HA 





Figure 18: WP1130 inhibits purified deubiquitinases. 
 
(C). Optimal concentrations of recombinant or immuno-purified deubiquitinase enzyme 
(USP5; 20 nM, UCH-L1; 20 nM, UCH-L3; 5 nM, USP 9x; immuno-isolated) were incubated in 
DUB activity buffer containing WP1130 or DMSO (v/v) in a 100 μl reaction volume for 30 min 
at 37ºC in 96-well fluorometry plates. After incubation, 500 nM Ub-AMC was added to the 











C12. WP1130 Modulates Pro- and Anti-Apoptotic proteins 
 USP5 is known to play a major role in maintaining the levels of unanchored 
polyubiquitin chains (181). Loss of USP5 has been reported to stabilize p53, due to the 
accumulation of free polyubiquitin chains which compete with ubiquitinated p53 (169). 
During the preparation of this dissertation, USP9x was described to enhance tumor cell 
survival by deubiquitinating the anti-apoptotic protein MCL-1, thereby promoting its 
stability (158).  The authors showed a positive correlation between the increased levels 
of MCL-1 and USP9x in lymphomas and multiple myelomas. siRNA mediated 
knockdown of USP9x led to rapid degradation of MCL-1, and sensitization of tumor cells 
to apoptotic stimuli. Considering these recent reports, we investigated the downstream 
effects of inhibiting USP9x and USP5 in Z138 cells. 
 Consistent with published reports, we observed an increase in p53 protein levels 
upon WP1130 treatment (Figure 19A, left). Co-treatment of Z138 cells with 
cyclohexamide (50 μg/ml) and WP1130 confirmed the stabilization rather than induction 
of p53 protein, as shown in Figure 19A (right). Furthermore, a rapid decline in MCL-1 
levels upon WP1130 treatment was observed (Figure 19B). To re-confirm the role 
played by USP9x and USP5 in regulating the levels of MCL-1 and p53 respectively, we 
performed siRNA based knockdown of USP9x and USP5 in HEK293T cells. Loss of 
USP9x led to ~50% decline in MCL-1 levels while loss of USP5 showed ~2-fold 
increase in p53 levels (Figure 20). Together these results demonstrate that WP1130 
inhibits selective cellular DUB activities, modulating the stability of both anti- and pro-












Figure 19: Effect of WP1130 on DUB regulated proteins. 
 
(A). Left - Z138 cells were incubated with DMSO (Control) or 5 μM WP1130 for 2 hours 
before total cell lysates were immunoblotted for p53 or actin as a protein loading control. 
Right – Z138 cells were treated with DMSO (Control), cycloheximide (CHX, 50 μg/ml) alone 
or combined with 5 μM WP1130 for 1 hr before whole cell lysate were immunoblotted for p53 
and actin as a protein loading control.  
 
(B). Whole cell extracts from Z138 cells were probed for the protein levels of MCL-1 and p53 
after WP1130 (5 μM) treatment for the indicated intervals. WP1130 treated cells show a rapid 












































Figure 20: Knockdown of USP5 and USP9x regulates p53 and MCL-1 levels. 
 
HEK293T cells were transfected with 30 nM siRNA targeting specific DUBs as described in 
the materials and methods. Extent of each DUB (USP9x, USP5) knockout and their impact 
on previously described targets was assessed by immunoblotting for p53, MCL-1 and USP14 




C13. Inhibitory effects of WP1130 are Thiol-Senstive 
 WP1130 contains α, ß unsaturated ketone group which are highly reactive 
towards sulfhydryl containing reagents via Michael’s addition reaction (182). Therefore, 
we investigated if the presence of reducing agents such as DTT has any impact on 
WP1130 mediated inhibition of the Jak2-Stat3 pathway and apoptosis. As shown in 
Figure 21A, the accumulation of Jak2 and ubiquitinated proteins in the insoluble fraction 
of WP1130 treated cells was completely blocked by the presence of DTT. Assessment 
of Jak2 ubiquitination from these cells showed a near complete inhibition of WP1130-
mediated ubiquitination of Jak2 (Figure 21B). These results prompted us to investigate 
whether IL-6 induced Stat3 phosphorylation, which is inhibited by WP1130, can be 
rescued in the presence of DTT.  We observed a complete restoration of IL-6 driven 
Jak2/Stat3 phosphorylation when Z138 cells were treated with combination of WP1130 
and DTT (Figure 21C, Lane 5). The cytotoxic effects of WP1130 were also completely 
abolished in the presence of DTT (Figure 21D). Accordingly, no DUB inhibition was 
seen in WP1130 and DTT co-treated Z138 cells (Figure 21E). This observation also 
correlates with the loss of in vitro DUB inhibition by WP1130 in the presence of DTT 
(Figure 21F). Such interference in WP1130’s growth-inhibitory or Jak2-inhibitory 
activities by DTT should not be confused with a possible oxidative stress induced by 
WP1130. To validate this, we examined the release of reactive-oxygen species (ROS) 
in Z138 cells treated with WP1130 and H2O2 (positive control) using DCFDA. No 
increase in the generation of any reactive-oxygen species was observed (Figure 22) in 
WP1130 treated cells, suggesting WP1130 does not induce an oxidative-stress which 
can be countered in the presence of DTT. Furthermore, oxidative stress has been 
suggested to activate, not inhibit, the Jak2/Stat3 pathway. AG490 itself has been shown 
to act as a reducing agent (183).   
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Figure 21: Inhibition of Jak2 signaling and protein ubiquitination by WP1130 is thiol-
sensitive. 
 
(A). Z138 cells were treated with DMSO (-), WP1130 (+) in the absence and presence of 1 
mM DTT for 2 hours. The lysates were prepared and probed for the presence of 
ubiquitinated proteins as well as Jak2 in the detergent-soluble and insoluble fraction of 
WP1130 treated cells. 
 
(B). Z138 cells were treated with DMSO (-), WP1130 (+) in the absence and presence of 1 
mM DTT for 2 hours. Following treatment, the cells were stimulated with 10 ng/ml IL-6. The 
cells were lysed to prepare whole cell extracts and probed for the activation of the Jak2-Stat3 
pathway. 
 
 (C). Flag-Jak2 HEK293 cells were treated with DMSO (-), WP1130 (+) in the absence and 

























































Figure 22: Inhibition of Jak2 signaling and protein ubiquitination by WP1130 is thiol-
sensitive (continued). 
 
(D). Z138 cells were incubated with increasing concentration of WP1130 in the presence and 
absence of 1 mM DTT for 3 days. The effect of WP1130, DTT alone or DTT+WP1130 on 
Z138 proliferation was assayed using MTT reagent. 
 
(E). Lysates from DMSO, WP1130, DTT and DTT+WP1130 treated cells were incubated with 
500 nM Ub-AMC to detect the changes in DUB activity. AMC fluorescence was monitored at 
380/460 em/ex. 
 
(F). Purified USP5 was incubated with DMSO, WP1130, DTT or DTT+WP1130 for 30 min. 






























































































Figure 22: WP130 does not induce reactive-oxygen species. 
 
Z138 cells were incubated with WP1130 (5 μM, black bars). DMSO (white bar) and 
H2O2 (1 mM, gray bars) for 1 hour. The cells were then washed twice in PBS, and 
incubated with 10 μM H2-DCFDA. After 10 mins of incubation, the cells were 
collected and the fluorescence of DCFDA was recorded as an indicator of generation 




D1. Suppression of Jak-Stat Signaling by WP1130 
 
 Given the essential role for Jak-Stat signaling in growth-promoting activities via 
a variety of cytokines, constitutive activation of Jaks would be expected to have 
pathological consequences. The Jak-Stat pathway is often found to be activated in most  
forms of cancer [Reviewed in (44), (45)]. Several growth factors and cytokines are 
expressed in most forms of cancer, including solid tumors and hematological 
malignancies, leading to autocrine activation of the Jak-Stat pathway inducing 
proliferative and anti-apoptotic effects (184-186). In addition, chromosomal 
translocations as well as point mutations within Jak2 have been shown to constitutively 
activate Jak2 kinase, independent of cytokine signaling.  Many Jak2-fusion 
proteins/mutations have been implicated in many hematological malignancies. Taken 
together, these reports project Jak2 as an attractive therapeutic target in cancer, 
validating the development of many small molecule inhibitors against Jak2 (187, 188).  
 Before the spur in the development of Jak2 inhibitors, tyrphostin AG490 was the 
only described inhibitor of Jak2 which induced tumor cell apoptosis and displayed anti-
tumor activities (69). Although AG490 inhibited the kinase activity of Jak2, requirements 
for high μM concentration limited its clinical potential and development. To develop a 
more potent inhibitor of Jak2 from the AG490 chemo-type, our research group screened 
a small library of AG490 analogues in cell based assays. WP1130, a lead compound 
from such a screen, inhibited cytokine-dependent (IL-3, IL-6) as well as constitutively 
active Jak2-Stat3 signaling at low μM concentrations. Although WP1130 is an analogue 
of AG490, it is unique and distinct from parental tyrphostin in its mechanism of action. 
While AG490 is a well known inhibitor of Jak2 kinase activity, WP1130 demonstrated no 
inhibition of Jak2-kinase activity (Figure 1 and 2).  
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 Initial studies with previous derivatives of WP1130 (WP1066) showed that 
WP1066 promotes Jak2 degradation (77), which leads to the suppression of 
downstream signaling. We too had observed a similar loss of Jak2 protein from the 
soluble lysates (Figure 4). However, we could not prevent the WP1130 mediated down-
regulation of Jak2 in the presence of major protease inhibitors (Figure 6). To elucidate 
the mechanism of suppression of Jak2-Stat3 signaling by WP1130, we modified our 
lysate preparation protocol to investigate the detergent-insoluble lysate as well. We 
observed a rapid, time- and concentration-dependent appearance of Jak2 in the 
detergent-insoluble fraction of WP1130 treated cells (Figure 7). Such a spatial 
relocalization of Jak2 from its normal cellular localization (cytosol, membrane) into the 
detergent-insoluble fraction prevents Jak2 from activating the downstream effector Stat 
proteins. Furthermore, using cellular fractionation studies as well as microscopic 
examination, our data provides several lines of evidence which show that WP1130 
promotes the accumulation of Jak2 into signaling incompetent aggresomes (Figure 10-
13). WP1130-induced sequestration of Jak2 from soluble to the insoluble fraction was 
highly specific for Jak2, as other members of Jak family (Jak1, Tyk2) did not show 
similar levels of accumulation in the insoluble fraction (Figure 7).   
 The accumulation of Jak2 into the detergent insoluble fraction of WP1130 
treated cells was accompanied by its rapid polyubiquitination. Immunoprecipitation of 
Jak2 under denaturing conditions from Z138 (endogenous) or from Flag-Jak2 
overexpressing HEK293 cells showed ubiquitination of Jak2 (Figure 14). Previous 
reports have described SOCS-1 dependent polyubiquitination of Jak2 in response to 
cytokine stimulation, which leads to its proteasomal degradation (38, 189). We 
observed an increased association between Jak2 and SOCS-1 after WP1130 
treatment, which explains the rapid ubiquitination of Jak2. However, the ubiquitination of 
Jak2 in WP1130 treated cells was independent of any cytokine-stimulation or new 
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protein synthesis, suggesting that WP1130 amplifies the resident, endogenous Jak2 
ubiquitination pathway many-fold, leading to its hyper-ubiquitination.  
 Using overexpression of lysine-specific mutants of HA-tagged ubiquitin, we 
observed a major accumulation of lysine-63 (K-63) linked ubiquitinated of Jak2 in 
WP1130 treated cells (Figure 15). On the other hand, we did not observe any significant 
increase in the accumulation of lysine-48 (K-48) linked polyubiquitinated Jak2 in 
WP1130 treated cells. Previous studies have demonstrated proteasomal degradation of 
ubiquitinated Jak2 (38). However, the proteasomal degradation of a protein is often 
attributed to the formation of lysine-48 linked polyubiquitin chains (86). The 
ubiquitination of Jak2 using K-63 linked ubiquitin chains is novel and has not previously 
been described. This is also in accordance with previous studies which have reported 
the accumulation of K-63 linked proteins into the insoluble fraction and aggresomes 
(175, 190).  
 We further showed that the inhibition of Jak2-Stat3 signaling pathway is linked 
intricately to the ubiquitination of Jak2. Since WP1130 contains an α, ß-unsaturated 
carbonyl group, it can interact with sulfhydryls through a Michael addition reaction (182). 
Such a modification should interfere with the anti-tumor activities of WP1130, and the 
suppression of Jak2-Stat3 signaling. We observed a complete restoration of Jak2-
driven Stat3 activation in cells treated with WP1130 and DTT. The accumulation of Jak2 
into the detergent-insoluble fraction was also completely abolished with the co-
treatment of WP1130 and DTT. This was further in correlation with the absence of Jak2 
ubiquitination in those cells (Figure 21). It should be noted that the DTT-induced 
interference in WP1130’s activities was not attributed to induction of oxidative stress (by 
WP1130) that could be quenched by a reducing agent (DTT).  We had observed no 
change in reactive-oxygen species (ROS) in WP1130 treated cells, which ruled out 
induction of oxidative stress as a contributor to its activity. Furthermore, oxidative stress 
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has been rather shown to activate the Jak2-Stat3 signaling pathway, not inhibit it (191) 
(Figure 22). 
 In summary, our study shows that WP1130 potently inhibits the Jak2-Stat3 
pathway by a unique mechanism involving rapid ubiquitination and aggresomal 
deposition of Jak2. In doing so, WP1130 blocked the activation of downstream Stat3 
signaling, contributing to the induction of apoptotic cell death.  
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D2. Modulation of DUB activity by WP1130 
 
 Ubiquitination and ubiquitin-like protein modification plays a major role in 
directing the fate and function of most cellular proteins (78). Several key enzymes in 
these pathways are amplified, or modified in diseased cells and provides rationale for 
development of small molecules that inhibit or modulate their activity. Major advances 
have been made in selective targeting of specific enzymes in these pathways; some 
with clinical impact (192). Due to the specialized role of DUBs in the ubiquitin cycle and 
their emerging role in control of multiple signaling pathways and oncoproteins, DUB 
inhibitors may be useful anti-cancer agents (164). In this manuscript, we describe the 
unexpected DUB inhibitory activity of WP1130; a novel small molecule derived from the 
Jak2 inhibitor AG490. WP1130 induces accumulation of polyubiquitinated proteins and 
promotes tumor cell apoptosis.  
 Peptide based potent, irreversible inhibitors of DUBs, such as ubiquitin aldehyde 
and ubiquitin vinyl sulfone (UbVS) have been previously described (165, 166). 
However, their therapeutic potential is limited by their high mol wt and limited cellular 
bioavailability. Other small molecule compounds, such as D12-prostaglandin J2 were 
initially shown to inhibit ubiquitin iso-peptidase activity in cells (IC50 30 μM) and cause 
cellular accumulation of ubiquitinated proteins and cell death (176). A key molecular 
determinant required for DUB inhibitory activity, α, ß-unsaturated ketone with sterically 
accessible ß-carbon, was noted in this compound and lead to the identification of 
additional inhibitors with similar activities, such as dibenzylideneacetone (DBA; IC50 20–
40 µM), curcumin (IC50 80-100 μM) and shikoccin (NSC-302979; IC50 15 μM). However, 
the profile of specific DUBs affected by these compounds has not been described (167).
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 Using multiple in vivo and in vitro assays, we provide mechanistic evidence that 
WP1130 acts as a partially selective DUB inhibitor. Our data shows that WP1130 
suppresses the activities of major cellular deubiquitinases such as USP5, UCH-L1, 
USP9x, USP14 and UCH37. Inhibition of multiple DUBs is likely to induce multiple and 
predictable cellular changes, such as: (i) increased accumulation of polyubiquitinated 
proteins/unanchored polyubiquitin chains (Figure 16), (ii) decline in the pool of 
monomeric ubiquitin (Figure 16A), (iii) slower rate of polyubiquitin disassembly (Figure 
16C), (iv) an overall decrease in individual DUB activities (Figure 18) and (v) effect 
cellular levels/activities of DUB regulated oncoproteins (Figure 19). 
 A marked increase in cellular ubiquitinated proteins, arising either due to 
proteasome inhibition or loss of cellular DUB activity can trigger aggresome formation 
(174, 177). Formation of aggresomes under conditions of stress results in a temporary 
cellular cytoprotective event, relocating vast amounts of accumulated ubiquitinated 
proteins to the aggresomal insoluble fraction (193). Our recent data suggests that 
WP1130 treatment causes accumulation of polyubiquitinated Jak2 and Bcr-Abl into 
detergent insoluble aggresomes, thereby suppressing tumor cell proliferation (Kapuria 
et al, Sun et al, unpublished data). Therefore, trafficking of oncoproteins which play a 
crucial role in proliferation, survival and growth factor signaling into the aggresome, 
where they are unable to function, is predicted to be detrimental to tumor cells. 
However, the DUB(s) that play a crucial role in regulating these oncogenic kinases are 
not currently known. Using xenograft mouse models of CML and melanoma, we have 
previously shown that WP1130 treatment effectively suppresses tumor growth in vivo 
(73). Together these observations suggest that WP1130 may act as a therapeutic agent 
through its effects on DUB activity.   
 It is noteworthy that several of the DUBs targeted by WP1130 have recently 
been shown to be key regulators of the stability and turnover of specific oncogenes and 
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apoptotic regulators, including Mcl-1 (158) and p53 (169). Other DUBs are suggested to 
play a direct role in transformation (153) and control of ubiquitinated protein entry into 
the proteasome (194). Still others that may be targeted by WP1130 have recently been 
shown to play a role in unregulated cell growth and tumor cell addiction (159). The role 
played by many other DUBs and their impact on their cognate substrates in the 
apoptotic activity engaged by WP1130 is not yet known.  
 The molecular basis of DUB inhibition by WP1130 is currently unknown. 
WP1130 contains α, ß-unsaturated carbonyl group that can hypothetically interact with 
sulfhydryl of cysteines found in the active sites of DUBs through a Michael addition 
reaction (182). However, similar carbonyl groups are found in AG490 but this molecule 
possesses no apparent DUB inhibitory activity in cells. Whether WP1130 inactivates 
DUBs by interacting with their active site cysteines remains to be determined. If so, 
other thiol-containing reagents such as DTT may also react with WP1130 and quench 
its activities. Interestingly, we have observed near complete loss of WP1130 mediated 
ubiquitination and apoptosis in the presence of DTT. This observation correlates with 
the loss of DUB inhibition by WP1130 in the presence of DTT (Figure 21). These 
observations may also suggest that active site cysteines and structural changes 
induced by sulfhydryl reduction and oxidation of DUBs may play a role in WP1130-
mediated DUB inhibitory activity and selectivity as well.  
 The full profile of DUBs that are affected by WP1130 is being further assessed. 
Crystal structures of several deubiquitinating enzymes have revealed a high degree of 
homology within their catalytic core (195, 196). This may account for the partial 
selectivity of WP1130 against a specific subset of DUBs. Further SAR studies to 
develop structural variants of WP1130 with increased target specificity may enhance 
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